Zydus receives final approval for Pioglitazone HCI tablets

Ahmedabad, 14 February 2013

Zydus Cadila has received the final approval from the USFDA to market Pioglitazone HCl tablets in different strengths of 15 mg, 30 mg and 45 mg. The drug falls in the anti-diabetics segment.

The estimated sales in 2012 as per IMS for Pioglitazone HCl tablets was USD 2 billion.

The group now has 75 approvals and has so far filed 170 ANDAs since the commencement of filing process in FY 2003-04.
